Biotech vets launch a neu­ro start­up with $54.5M to kick­start R&D

More than 2 years af­ter Kath­leen Sere­da Glaub and An­tho­ny Ford helped line up a $1.25 bil­lion deal to sell Af­fer­ent Phar­ma­ceu­ti­cals to Mer­ck, the two are back with a new start­up that has round­ed up $54.5 mil­lion in ven­ture cash with plans to pur­sue some new ap­proach­es to neu­ro­sciences.

Li­cens­ing tech out of the lab of Stan­ford’s Mehrdad Sham­loo, the two ex­ecs have kick­start­ed CuraSen Ther­a­peu­tics in­to ex­is­tence, work­ing on small mol­e­cules that are de­signed to tar­get re­cep­tors “to com­pen­sate for crit­i­cal neu­ronal and glial func­tions that have oth­er­wise been lost due to de­gen­er­a­tion.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.